Prime Medicine PRME EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's EPS (diluted)?
- Prime Medicine (PRME) reported EPS (diluted) of -$0.28 in Q1 2026.
- How has Prime Medicine's EPS (diluted) changed year-over-year?
- Prime Medicine's EPS (diluted) increased by 30.0% year-over-year, from -$0.40 to -$0.28.
- What is the long-term trend for Prime Medicine's EPS (diluted)?
- Over 2 years (2023 to 2025), Prime Medicine's EPS (diluted) has grown at a -20.7% compound annual growth rate (CAGR), from -$2.18 to -$1.37.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.